MG@PD@TiO2 nanocomposite based magnetic solid phase extraction coupled with LC-MS/MS for determination of lysophosphatidylcholines biomarkers of plasma in psoriasis patients.
MG@PD@TiO2 nanocomposite based magnetic solid phase extraction coupled with LC-MS/MS for determination of lysophosphatidylcholines biomarkers of plasma in psoriasis patients.
复制标题
DOI：
10.1016/j.jpba.2021.114101
复制
发表时间：
2021-05
影响因子：
3.4
通讯作者：
Xinying He;Han Cao;Xia Li;Yan Li;Yunqiu Yu
中科院分区：
文献类型：
--
作者：
Xinying He;Han Cao;Xia Li;Yan Li;Yunqiu Yu
溶血磷脂酰胆碱（Lysophosphatidylcholine，LPC）是一类与银屑病等多种疾病密切相关的代谢产物，其准确测定对疾病的诊断和预测具有重要意义。然而，由于生物样品的巨大复杂性和杂质干扰，这是具有挑战性和复杂性的。本研究合成了磁性纳米复合材料MG@PD@TiO2，并利用LPCs中磷酸基团与MG@PD@TiO2纳米材料上钛离子之间的刘易斯酸碱相互作用，从复杂的生物基质中选择性分离富集LPCs。将MG@PD@TiO2纳米材料固相萃取样品前处理过程与LC-MS/MS联用技术应用于人血浆中6种典型LPC（LPC 10：0、14：0、16：0、18：0、18：1、22：0）的实际测定。通过单因素试验（吸附剂用量、吸附和解吸时间、洗脱溶剂种类、洗脱液体积）对提取条件进行了科学优化。在优化条件下，LPC 10：0和LPC 14：0的检出限（LOD，S/N = 3）和定量限（LOQ，S/N = 10）分别为1和5 ng/mL，LPC 16：0和LPC 18：1的检出限（LOD，S/N = 3）和定量限（LOQ，S/N = 10）分别为0.02和0.1 ng/mL，LPC 18：0和LPC 22：0的检出限（LOD，S/N = 3）和定量限（LOQ，S/N = 10）分别为0.05和0.2 ng/mL。日内和日间精密度分别为3.82- 12.60%（n = 6）和3.29- 13.50%（n = 6），回收率在91.92- 113.69%之间，分析物在基质中的稳定性良好，RSD ≤ 15.51%。最后，所开发的方法成功地应用于准确测定血浆中的6个LPC生物标志物在银屑病患者（n = 10）和对照组（n = 10）。
Lysophosphatidylcholine (LPC) was commonly known as a class of significant differential metabolites of high relevance with many diseases including psoriasis, of which the accurate determination is of great importance to diagnosis or prediction to many diseases. However, it is challenging and complicated because of the enormous biological sample complexity and impurities interference. In this study, we synthesized a magnetic nanocomposite MG@PD@TiO2and took advantage of the interactions of Lewis acid−base between the phosphate groups in LPCs and Ti ions on MG@PD@TiO2nanomaterials for selective separation and enrichment of LPCs from complex biological matrix. The solid-phase extraction sample pretreatment process by means of MG@PD@TiO2nanomaterials coupled with LC–MS/MS method was then applied to actual determination of six typical LPCs (LPC 10:0, 14:0, 16:0, 18:0, 18:1, 22:0) in human plasma. The extraction conditions were scientifically optimized by single-factor test (adsorbent amount, adsorption and desorption time, elution solvent type, eluant volume). Under the optimal conditions, the detection limits (LOD, S/N = 3) and quantification limits (LOQ, S/N = 10) were 1 and 5 ng/mL for LPC 10:0 and LPC 14:0, 0.02 and 0.1 ng/mL for LPC 16:0 and LPC 18:1, 0.05 and 0.2 ng/mL LPC 18:0 and LPC 22:0, respectively. The intra- and inter-day precisions were 3.82–12.60 % (n = 6) and 3.29–13.50 % (n = 6) respectively, the recoveries were in the range of 91.92–113.69 % and the stability of the analytes in the matrix performed well with RSDs≤15.51 %. Finally, the developed method was successfully applied to the accurate determination of six LPCs biomarkers of plasma in patients with psoriasis (n = 10) and control groups (n = 10).